UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48
UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $48.
Read original at benzingaStocks · News reference
Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
Teva Pharma is trading higher after announcing positive topline results from a Phase 2a study of TEV '408, which met its primary endpoint.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study
Teva reports positive Phase 2a results for TEV '408, successfully preventing gluten-induced intestinal damage in adult celiac patients.
Read original at benzingaTeva Pharmaceutical Industries shares are trading higher after the company announced topline results from an ongoing Phase 2a study of TEV ‘408. The study met its primary endpoint.
Read original at benzinga